PriceTargets.com logo

Recursion Pharmaceuticals - RXRX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $12.75
  • Forecasted Upside: 67.76%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.60 As of 04/22/2024 01:00 AM ET
▲ +0.25 (3.40%)

This chart shows the closing price for RXRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Recursion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RXRX

Analyst Price Target is $12.75
▲ +67.76% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Recursion Pharmaceuticals in the last 3 months. The average price target is $12.75, with a high forecast of $17.00 and a low forecast of $8.00. The average price target represents a 67.76% upside from the last price of $7.60.

This chart shows the closing price for RXRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Recursion Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$17.00Low
3/4/2024KeyCorpBoost TargetOverweight ➝ Overweight$15.00 ➝ $16.00Low
2/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$15.00 ➝ $17.00Low
1/26/2024TD CowenInitiated CoverageMarket PerformLow
1/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00Low
11/13/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$11.00 ➝ $10.00Low
11/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$17.00 ➝ $15.00Low
9/5/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$17.00Low
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$17.00Low
7/18/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$17.00Low
7/13/2023KeyCorpBoost Target$12.00 ➝ $15.00Low
5/22/2023Morgan StanleyInitiated CoverageEqual Weight$8.00Low
3/16/2023Needham & Company LLCInitiated CoverageBuy$17.00Low
1/23/2023SVB LeerinkLower TargetMarket Perform$9.00 ➝ $8.00Low
11/9/2022The Goldman Sachs GroupBoost TargetNeutral$8.00 ➝ $9.00Low
10/25/2022SVB LeerinkLower TargetMarket Perform$10.00 ➝ $9.00Low
9/15/2022KeyCorpInitiated CoverageOverweight$20.00Low
8/11/2022The Goldman Sachs GroupBoost TargetNeutral$7.00 ➝ $8.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$9.00 ➝ $7.00Low
4/18/2022Bank of AmericaDowngradeBuy ➝ Neutral$10.00High
3/24/2022The Goldman Sachs GroupLower TargetNeutral$32.00 ➝ $10.00Low
3/4/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$32.00 ➝ $10.00High
12/8/2021SVB LeerinkBoost TargetOutperform$30.00 ➝ $32.00High
9/21/2021Berenberg BankInitiated CoverageBuy$37.00Medium
8/16/2021SVB LeerinkLower TargetOutperform$33.00 ➝ $30.00High
5/11/2021SVB LeerinkInitiated CoverageOutperform$33.00High
5/11/2021JPMorgan Chase & Co.Initiated CoverageNeutral$32.00High
5/11/2021The Goldman Sachs GroupInitiated CoverageNeutral$34.00High
5/11/2021Bank of AmericaInitiated CoverageBuy$31.00High
5/11/2021KeyCorpInitiated CoverageOverweight$36.00High
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2023
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2023
  • 8 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2024
  • 19 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2024
  • 22 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/23/2024
  • 17 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2024

Current Sentiment

  • 17 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Recursion Pharmaceuticals logo
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $7.60
Low: $7.21
High: $7.79

50 Day Range

MA: $10.66
Low: $7.35
High: $15.52

52 Week Range

Now: $7.60
Low: $4.54
High: $16.75

Volume

3,942,634 shs

Average Volume

4,071,819 shs

Market Capitalization

$1.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Recursion Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Recursion Pharmaceuticals in the last year: JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Needham & Company LLC, and TD Cowen.
View the latest analyst ratings for RXRX.

What is the current price target for Recursion Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Recursion Pharmaceuticals in the last year. Their average twelve-month price target is $12.75, suggesting a possible upside of 67.8%. Needham & Company LLC has the highest price target set, predicting RXRX will reach $17.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $8.00 for Recursion Pharmaceuticals in the next year.
View the latest price targets for RXRX.

What is the current consensus analyst rating for Recursion Pharmaceuticals?

Recursion Pharmaceuticals currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RXRX, but not buy more shares or sell existing shares.
View the latest ratings for RXRX.

What other companies compete with Recursion Pharmaceuticals?

Other companies that are similar to Recursion Pharmaceuticals include Ambrx Biopharma, Schrödinger, Fusion Pharmaceuticals, Neumora Therapeutics and Sana Biotechnology. Learn More about companies similar to Recursion Pharmaceuticals.

How do I contact Recursion Pharmaceuticals' investor relations team?

Recursion Pharmaceuticals' physical mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The company's listed phone number is 385-269-0203 and its investor relations email address is [email protected]. The official website for Recursion Pharmaceuticals is www.recursion.com. Learn More about contacing Recursion Pharmaceuticals investor relations.